Clopidogrel pharmacology

Pharmacology Clopidogrel is a thienopyridine derivative, chemically related to ticlopidine, that inhibits platelet aggregation. It acts by irreversibly modifying the platelet ADP receptor. Conseguently, platelets exposed to clopidogrel are affected for the remainder of their lifespan. 

Richter, T., Miirdter, T.E., Heinkele, G., Pleiss, J., Tatzel, S., Schwab, M., Eichelbaum, M. and Zanger, U.M. (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. Journal of Pharmacology... 

Dual antiplatelet (DAP) therapy with clopidogrel and aspirin remains the cornerstone of post-PCI pharmacologic management (58,59). The current recommended duration of clopidogrel post-stent placement... 

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38 92-99... 

Platelet inhibitors are widely used in the treatment and prevention of coronary artery disease. In addition to acetic salicylic acid (ASA), two major groups of platelet inhibitors are used phosphodiesterase inhibitors, including dipyridamole, and thienopyridines. Clopidogrel is the most widely used antiplatelet agent and in combination with ASA, it is the standard-of-care (SoC) for acute coronary s5mdromes and percutaneous coronary interventions. However, the mechanisms of action include pathways that affect the metabolic activity of bone cells and pharmacologic modulation of these pathways may have adverse effects on the bones. 

---